New Chemical Modalities and Strategic Thinking in Early Drug Discovery
被引:80
|
作者:
Blanco, Maria-Jesus
论文数: 0引用数: 0
h-index: 0
机构:
Sage Therapeut Inc, Med Chem, 215 First St, Cambridge, MA 02142 USASage Therapeut Inc, Med Chem, 215 First St, Cambridge, MA 02142 USA
Blanco, Maria-Jesus
[1
]
Gardinier, Kevin M.
论文数: 0引用数: 0
h-index: 0
机构:
Novartis Inst BioMed Res, Global Discovery Chem, 22 Windsor St, Cambridge, MA 02139 USASage Therapeut Inc, Med Chem, 215 First St, Cambridge, MA 02142 USA
Gardinier, Kevin M.
[2
]
机构:
[1] Sage Therapeut Inc, Med Chem, 215 First St, Cambridge, MA 02142 USA
[2] Novartis Inst BioMed Res, Global Discovery Chem, 22 Windsor St, Cambridge, MA 02139 USA
Chemical modalities;
RNA;
PROTAC;
cyclopeptides;
target validation;
strategy;
TARGET;
D O I:
10.1021/acsmedchemlett.9b00582
中图分类号:
R914 [药物化学];
学科分类号:
100701 ;
摘要:
The classical toolbox for drug discovery is continuously expanding beyond traditional small molecules. New chemical modalities including RNA therapeutics, protein degraders, cyclopeptides, antibody drug conjugates, and gene therapy have matured, demonstrating clinical success and are now considered early in target appraisal. In this Viewpoint, we highlight recent progress in the field.